RegulationPriority Review (US), Fast Track (US), Orphan Drug (US), Orphan Drug (EU), Priority Review (CN), Breakthrough Therapy (CN), Orphan Drug (KR), Promising Innovative Medicine (GB), Paediatric investigation plan (EU)

Structure/Sequence

Sequence Code 18457995

Source: *****

Clinical Trials associated with Efgartigimod Alfa

NCT06765161

/ RecruitingPhase 3IIT

Efgartigimod in IVIG Dependent Myasthenia Gravis Patients

This study is an open label, single center, prospective, 26 weeks study with descriptive analysis where IVIG is replaced by efgartigimod therapy. MG-ADL and MGQOL evaluations will occur weekly throughout the study to week 26.

Start Date06 Feb 2025

Sponsor / Collaborator

Clinique Neuro-Outaouais

[+1]

NCT06827587

/ Not yet recruitingNot ApplicableIIT

Efficacy, Safety, and PKPD Study of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis (gMG): an Open-label, Randomized Controlled Trial

Title: The Efficacy, Safety, and PK/PD of Efgartigimod Followed by Telitacicept in Generalized Myasthenia Gravis: Protocol of a Randomized Controlled Trial Objective: This study aims to evaluate the efficacy, safety, and pharmacokinetics/pharmacodynamics (PK/PD) of efgartigimod followed by telitacicept in patients with generalized myasthenia gravis (gMG). Specifically, the trial seeks to determine the optimal treatment strategy for gMG by assessing the effect of sequential biologic therapy on disease management.
Study Design: This is a multi-center, open-label, randomized controlled trial involving 60 acetylcholine receptor antibody-positive gMG patients.

Start Date01 Feb 2025

Sponsor / Collaborator

First Affiliated Hospital of Wenzhou Medical University

[+3]

CTIS2024-517511-70-00

/ RecruitingPhase 1

- ARGX-113-2405

Start Date12 Dec 2024

Sponsor / Collaborator

Argenx BV

100 Clinical Results associated with Efgartigimod Alfa

100 Translational Medicine associated with Efgartigimod Alfa

100 Patents (Medical) associated with Efgartigimod Alfa

151

Literatures (Medical) associated with Efgartigimod Alfa

01 Mar 2025·BRAIN BEHAVIOR AND IMMUNITY

Reducing IgG accumulation via neonatal Fc receptor (FcRn) blockade relieves neuropathic pain

Article

Author: Fiore, Nathan T ; Dayani, Dorsa ; Zuberi, Younus A ; Willcox, Kendal F ; Heijnen, Cobi J ; Grace, Peter M

Preclinical and clinical studies have established that autoreactive immunoglobulin G (IgG) can drive neuropathic pain. We recently demonstrated that sciatic nerve chronic constriction injury (CCI) in male and female mice results in the production of pronociceptive IgG, which accumulates around the lumbar region, including within the dorsal root ganglia (DRG) and spinal cord, facilitating the development of neuropathic pain. These data raise the intriguing possibility that neuropathic pain may be alleviated by reducing the accumulation of IgG. To this end, we tested whether biologic inhibition or genetic deletion of the neonatal Fc receptor (FcRn) would attenuate mechanical hypersensitivity (allodynia) and IgG deposition induced by CCI. FcRn are prominently expressed on myeloid and endothelial cells and extend the half-life of IgG via pinocytosis and recycling into the extracellular milieu. We show here that administration of the FcRn blocker efgartigimod either 7- or 28-days post-CCI relieved allodynia among both male and female mice, compared to the Fc fragment control. Efgartigimod, administered systemically (intraperitoneal) or to the lumbar region (intrathecal), attenuated mechanical allodynia for at least one month w. CCI-induced allodynia was similarly reduced in FcRn-deficient (FcRn^-) mice compared to wild-type mice. Biologic inhibition or genetic deletion of FcRn also reduced CCI-induced accumulation of IgG on macrophages and neurons in lumbar DRG, as well as microglia in the lumbar dorsal spinal cord. Expression of the Fc receptor γ subunit (FcRγ) was reduced in efgartigimod-treated or FcRn^- mice post-CCI compared to controls. The FcRγ subunit is a key component of Fc gamma receptors (FcγRs), which are activated by IgG immune complexes. In macrophage cultures stimulated by IgG immune complexes, FcRn blockade also dampened FcγR-dependent production of proinflammatory cytokines. Collectively, our study demonstrates that FcRn blockade or deletion alleviates mechanical allodynia and reduces IgG accumulation after CCI, attenuating pronociceptive IgG-FcγR signaling around the lumbar region. Strategies to block FcRn and reduce IgG recycling warrant further investigation as potential treatments for IgG-mediated neuropathic pain.

01 Mar 2025·MUSCLE & NERVE

Individualized Dosing of Efgartigimod in Patients With Generalized Myasthenia Gravis: Clinical Experience at a Single Center

Article

Author: Silvestri, Nicholas J.

ABSTRACT:

Introduction/Aims:

Neonatal Fc receptor (FcRn) inhibitors represent a promising treatment option for patients with generalized myasthenia gravis (gMG); however, data on clinical use are limited. The aim of this report is to describe one center's approach to efgartigimod dosing in patients with gMG.

Methods:

Medical records of patients with acetylcholine receptor antibody‐positive (AChR‐Ab+) gMG whose symptoms were not adequately controlled by oral medications and/or intravenous immunoglobulin who received efgartigimod between January 2022 and January 2024 were retrospectively evaluated. The first three efgartigimod cycles (10 mg/kg IV) were initiated at fixed intervals (4 once‐weekly infusions, with 4 weeks between cycles). After the third cycle, initiation of subsequent treatment cycles and time between cycles were determined individually by clinical evaluation. Effectiveness was measured by the Myasthenia Gravis Activities of Daily Living (MG‐ADL) scale. Adverse events and changes to concomitant therapies were monitored.

Results:

Nineteen patients were included and received a mean of 4.4 efgartigimod cycles, including two patients who discontinued after two cycles. All patients exhibited a clinically meaningful improvement in MG‐ADL total score from baseline to the end of the last cycle, with a mean improvement of 5.8 points. Seven (37%) patients achieved minimal symptom expression (MSE, MG‐ADL 0–1). From baseline to the end of the last cycle, daily prednisone dose was decreased or it was discontinued, while two patients initiated prednisone. Efgartigimod was generally well tolerated.

Discussion:

This approach to efgartigimod dosing resulted in substantial MG‐ADL score improvement in these patients with AChR‐Ab+ gMG as well as reduced daily dose and/or discontinuation of concomitant corticosteroids.

11 Feb 2025·NEUROLOGY

Randomized Phase 2 Study of FcRn Antagonist Efgartigimod in Generalized Myasthenia Gravis

Article

262

News (Medical) associated with Efgartigimod Alfa

13 Jan 2025

·www.globenewswire.com

argenx Highlights 2025 Strategic Priorities

Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales Pre-filled syringe FDA PDUFA on track for April 2025 to support reaching patients earlier in treatment paradigm 10 ongoing registrational studies in 2025 across efgartigimod and empasiprubart enable next wave of indications Empasiprubart to be evaluated in two head-to-head registrational studies against IVIg to position C2 inhibitor for broad, early-line use in MMN and CIDP Transition to sustainable profitability in 2025 enables continued investment in innovation January 13, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported preliminary financial results for the full-year 2024, including global product net sales, and announced its strategic priorities for 2025. “2024 was a transformative year as we significantly expanded our global patient reach with VYVGART and advanced a world-class pipeline of precision therapies,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx. “The team’s strong execution has positioned argenx to be a profitable company in 2025, providing us flexibility to invest in the next wave of innovation across the company. Today, we are all in on our innovation mission, applying our successful innovation playbook to bring transformational outcomes to even more patients by unleashing the next wave of autoimmune indications and therapies, and securing our future by advancing multiple programs against first-in-class targets. We are positioned for significant expansion in 2025 with the FDA decision on approval of our pre-filled syringe, global CIDP rollout, and label-expansion studies underway for MG. To further support our growth, we are thrilled to have 10 ongoing registrational and 10 proof-of-concept studies in 2025, teeing us up for several data readouts across our pipeline in the next 12-24 months. “Innovation is the cornerstone of everything we do, from the foundational science all the way to payor negotiations; it is our goal to deliver innovative and disruptive science for the benefit of patients who need better access to transformational safe, effective, and convenient precision therapies. Innovation has no meaning unless it reaches the marketplace, and we will continue to prioritize patient outcomes in all that we do.” 2025 Strategic Priorities argenx established its ‘Vision 2030’ to outline the next phase of growth as part of its long-term commitment to transform the treatment of autoimmune diseases. Through this vision, argenx aims to treat 50,000 patients globally with its medicines, secure 10 labeled indications across all approved medicines, and advance five pipeline candidates into Phase 3 development by 2030. To achieve the goals set out in its ‘Vision 2030’, argenx has set the following priorities for 2025: Expand the global VYVGART opportunity by reaching more patients broadly across MG, CIDP and ITP through additional regulatory approvals and continuous evidence generationLaunch VYVGART SC as a pre-filled syringe to innovate on the patient experience and move earlier in the MG and CIDP treatment paradigmsExecute 10 registrational and 10 proof-of-concept studies to fuel pipeline growth across efgartigimod, empasiprubart and ARGX-119Advance four new molecules into Phase 1 development, expanding the next wave of innovationGenerate sustainable value through continued investment in the Immunology Innovation Program, focused on first-in-class, antibody-based medicines with pipeline-in-a-product potential Expand the global VYVGART opportunity and launch VYVGART SC as a pre-filled syringe VYVGART® (IV: efgartigimod alfa-fcab and SC: efgartigimod alfa and hyaluronidase-qvfc) is a first-in-class FcRn blocker approved in three indications, including generalized myasthenia gravis (gMG) globally, primary immune thrombocytopenia (ITP) in Japan, and chronic inflammatory demyelinating polyneuropathy (CIDP) in the U.S., Japan, and China. Regulatory decisions on approval of VYVGART for gMG expected in first half of 2025, including in Israel (SC), South Korea (IV), and Kuwait (IV)Continued innovation around the patient experience for VYVGART SC, including four key regulatory decisions on approval expected in 2025 FDA review ongoing of pre-filled syringe (PFS) for gMG and CIDP with Prescription Drug User Fee Act (PDUFA) target action date of April 10, 2025PFS decisions on approval for gMG and CIDP expected in Europe in first half of 2025 and Japan and Canada in second half of 2025Autoinjector development underway with launch planned for 2027 Evidence generation through Phase 4 and label-enabling studies in MG, CIDP and ITP Label-enabling studies ongoing to reach broader MG populations, including ADAPT-SERON (seronegative gMG), ADAPT-JR (pediatric) and ADAPT-OCULUS (ocular MG), with topline results expected in second half of 2025 (SERON) and first half of 2026 (OCULUS and JR)Phase 4 switch study ongoing in CIDP to inform treatment decisions when switching a patient on IVIg to VYVGART SCADVANCE-NEXT confirmatory study ongoing of VYVGART IV in primary ITP to support FDA submission with topline results expected in second half of 2026 Execute 10 registrational and 10 proof-of-concept studies across efgartigimod, empasiprubart and ARGX-119 argenx continues to demonstrate breadth and depth within its immunology pipeline, advancing multiple first-in-class product candidates with potential across multiple high-need indications. argenx is solidifying its leadership in FcRn biology with efgartigimod, complement inhibition with empasiprubart and in the role of MuSK at the neuromuscular junction with ARGX-119. In 2025, argenx plans to execute 10 registrational and 10 proof-of-concept studies across efgartigimod, empasiprubart and ARGX-119 to advance its next wave of launches. Efgartigimod DevelopmentEfgartigimod is being evaluated in more than 15 severe autoimmune diseases (including MG, CIDP and ITP), exploring the significance of FcRn biology across neurology and rheumatology indications, as well as new therapeutic areas. To prioritize those indications that can drive transformative benefit, argenx has made the decision to discontinue development of efgartigimod in bullous pemphigoid (BP). Registrational ALKIVIA study ongoing evaluating three myositis subsets (immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and dermatomyositis (DM); topline results expected in second half of 2026Two registrational UplighTED studies ongoing in thyroid eye disease (TED); topline results expected in second half of 2026Registrational UNITY study ongoing in primary Sjögren’s disease; topline results expected in 2027Decision made to discontinue development in BP based on results from 98 patients in the Phase 2 BALLAD studyProof of concept studies ongoing in lupus nephritis (LN), systemic sclerosis (SSc) and antibody mediated rejection (AMR); topline results expected in LN in fourth quarter of 2025, SSc in second half of 2026, and AMR in 2027Two new indications nominated, including autoimmune encephalitis (AIE) and one that will be disclosed later in 2025Externally sponsored research studies ongoing in early MG, MG crisis, Guillain-Barré syndrome (GBS), stiff person syndrome (SPS), and neuromyelitis optica spectrum disorder (NMO-SD) Empasiprubart Development argenx is evaluating empasiprubart in registrational studies in multifocal motor neuropathy (MMN) and CIDP, and proof-of-concept studies in delayed graft function (DGF) and DM. Registrational EMPASSION study ongoing in MMN evaluating empasiprubart head-to-head versus IVIg; topline results expected in second half of 2026Registrational EMVIGORATE study in CIDP evaluating empasiprubart head-to-head versus IVIg to start in first half of 2025Proof of concept studies ongoing in DGF and DM; topline results expected in DGF in second half of 2025 and in DM in first half of 2026 ARGX-119 Developmentargenx is evaluating ARGX-119 in congenital myasthenic syndromes (CMS), amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA). Phase 1b proof-of-concept study ongoing in CMS; topline results expected in second half of 2025Phase 2a proof-of-concept study ongoing in ALS; topline results expected in first half of 2026SMA nominated as third indication with proof-of-concept study to start in 2025 Advance four new pipeline molecules and generate sustainable value through continued investment in Immunology Innovation Program argenx continues to invest in its Immunology Innovation Program (IIP) to drive long-term sustainable pipeline growth. Through the IIP, four new pipeline candidates have been nominated, including: ARGX- 213, targeting FcRn and further solidifying argenx’s leadership in this new class of medicine; ARGX- 121, a first-in-class molecule targeting IgA; ARGX-109, targeting IL-6, which plays an important role in inflammation, and ARGX-220, a first-in-class sweeping antibody for which the target has not yet been disclosed. Investigational new drug (IND) applications to be filed in 2025 for ARGX-213, ARGX-121, ARGX-109 and ARGX-220; Phase 1 results expected for ARGX-109 in second half of 2025 and for ARGX-213 and ARGX-121 in first half of 2026 Preliminary* Fourth Quarter and Full-Year 2024 Financial Results Today, argenx also announced preliminary* global product net sales for the fourth quarter and full-year 2024 of approximately $737 million and $2.2 billion, respectively. As of December 31, 2024, argenx had approximately $3.4 billion in cash, cash equivalents and current financial assets*. * - The preliminary selected financial information is unaudited, subject to adjustment, and provided as an approximation in advance of the company’s announcement of complete financial results in February 2025. Refer to the Preliminary Financial Results note in this document. 2025 Financial Guidance Based on its current operating plans, argenx expects its combined R&D and SG&A expenses in 2025 to be approximately $2.5 billion. 43rd Annual J.P. Morgan Healthcare Conference Presentation and Webcast Tim Van Hauwermeiren will highlight these updates in a corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference today, Monday, January 13, 2025, at 9:45 a.m. PT. The live webcast of the presentation may be accessed under Investors on the argenx website. A replay will be available for 30 days following the presentation. About VYVGART and VYVGART SC VYVGART® is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG autoantibodies. It is the first approved FcRn blocker for the treatment of generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and primary immune thrombocytopenia (ITP). VYVGART SC is a subcutaneous combination of efgartigimod alfa and recombinant human hyaluronidase PH20 (rHuPH20), Halozyme’s ENHANZE® drug delivery technology to facilitate subcutaneous injection delivery of biologics. It is marketed as VYVGART® Hytrulo in the U.S., VYVGART SC in Europe, VYVDURA® in Japan, and may be marketed under different proprietary names following approval in other regions. About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, X (formerly known as Twitter), and Instagram. Media: Ben Petokbpetok@argenx.com Investors: Alexandra Roy (US)aroy@argenx.com Lynn Elton (EU)lelton@argenx.com Preliminary Financial Results The financial information presented in this press release is preliminary, estimated, and unaudited. They are subject to the completion and finalization of argenx’s financial and accounting closing procedures. They reflect management’s estimates based solely upon information available to management as of the date of this press release. Further information learned during that completion and finalization may alter the final results. In addition, the preliminary estimates should not be viewed as a substitute for full quarterly and annual financial statements prepared in accordance with IFRS. There is a possibility that argenx’s financial results for the quarter ended December 31, 2024, and full year financial results for 2024 could vary materially from these preliminary estimates. In addition to the completion of the financial closing procedures, factors that could cause actual results to differ from those described above are set forth below. Accordingly, you should not place undue reliance upon this preliminary information. Additional information regarding the company’s fourth quarter 2024 financial results and full year financial results for 2024 will be available in the company’s annual report and Form 20-F, which will be filed with the Netherlands Authority for the Financial Markets and U.S. Securities and Exchange Commission (the “SEC”), respectively. Forward Looking Statements The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “aim,” “can,” “continue,” “expect,” “goal,” “may,” “ongoing,” “plan,” “possible,” “target,” and “will,” and include statements argenx makes regarding its expected profitability in 2025; its 2025 strategic priorities, including its launch of pre-filled syringes, 10 Phase 3 studies and 10 Phase 2 studies across efgartigimod, empasiprubart and ARGX-119, the advancement of four molecules in Phase 1 studies and the continued investment in the Immunology Innovation Program; its significant expansion in 2025; the continued growth of VYVGART, including its expected autoinjector launch in 2027 and four global decisions in 2025; its expectations regarding the continued growth in CIDP, including its plan to launch multiple CIDP products in 2025 and the expected timing of the EMVIGORATE study; its expectations regarding the growth of the MMN market opportunity, including the expected timing of the EMPASSION study; the anticipated timing of data readouts and regulatory milestones and plans, including the timing of planned clinical trials and regulatory filings and approvals; its vision for 2030, including having 5 new molecules in Phase 3, 10 labeled indications and having 50,000 patients on treatment; the anticipated timing of pending regulatory decisions in Israel, South Korea, Kuwait, the U.S., Europe, Japan and Canada; the expected timing of Phase 4 and label-enabling studies in MG, CIDP and ITP; and its expected 2025 research and development and selling, general and administrative expenses. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including the results of argenx's clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements in products and product candidates; the acceptance of argenx's products and product candidates by patients as safe, effective and cost-effective; the impact of governmental laws and regulations on our business; disruptions caused on our reliance of third party suppliers, service providers and manufacturing; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.

Drug ApprovalPhase 1Phase 2Clinical ResultPhase 3

30 Dec 2024

·www.prnewswire.com

Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy

SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co-formulated with Halozyme's ENHANZE® drug delivery technology, was granted regulatory approval by Japan's Ministry of Health, Labour and Welfare (MHLW) for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVDURA was approved for CIDP as a once weekly 30-to-90 second subcutaneous injection, which can be self-administered at home, and is the first and only neonatal Fc receptor (FcRn) blocker approved for the treatment of CIDP. "We are pleased that VYVDURA, with our innovative ENHANZE drug delivery technology, is now approved for two indications in Japan, enabling greater flexibility and optionality for generalized myasthenia gravis and CIDP patients," said Dr. Helen Torley, president and chief executive officer of Halozyme. "We look forward to VYVDURA being a new treatment option for an even broader number of patients in Japan." The MHLW approval is based on the ADHERE Study, the largest clinical trial to date studying CIDP. In the ADHERE study, 69% (221/322) of patients treated with VYVDURA, regardless of prior treatment, demonstrated evidence of clinical improvement, including improvements in mobility, function and strength. ADHERE met its primary endpoint (p<0.0001) demonstrating a 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in the risk of relapse versus placebo. Ninety-nine percent of trial participants elected to participate in the ADHERE+ open-label extension. The safety results were generally consistent with the known safety profile of VYVDURA in previous clinical studies and real-world use. VYVDURA was also approved by the MHLW for manufacturing and marketing in January 2024 and launched in April 2024 for the treatment of generalized myasthenia gravis (gMG). In March 2024, VYVDURA was designated as an Orphan Drug for the treatment of CIDP by the MHLW. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched more than 800,000 patient lives in post-marketing use in nine commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients, including offering flexibility to receive treatment in more convenient locations and broadening the treatment options for the indications referred to in this press release. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected results or delays in launch or commercialization of our partner's product for the indication referred to in this press release, unexpected adverse events or patient experiences or outcomes from being treated with the ENHANZE® co-formulated treatment referred to in this press release, and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contacts: Tram Bui VP, Investor Relations and Corporate Communications 609-359-3016 [email protected] Samantha Gaspar Teneo 212-886-9356 [email protected] SOURCE Halozyme Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalOrphan DrugClinical Result

27 Dec 2024

·pipelinereview.com

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

VYVDURA ® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx’s VYVGART ® and VYVDURA portfolio approved in Japan for three indications – first country globally with access across three indications AMSTERDAM, The Netherlands I December 27, 2024 I argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVDURA is approved for CIDP as a once weekly 30-to-90 second subcutaneous injection, which can be self-administered at home, and is the first and only neonatal Fc receptor (FcRn) blocker approved for the treatment of CIDP. “CIDP is a rare and debilitating disease for which there has been little innovation in treatment in 30 years,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer of argenx. “With VYVDURA, CIDP patients in Japan now have access to a novel therapy with a focused mode of action offering a convenient 30-to-90 second at-home self-injection option with an established efficacy and safety profile, as demonstrated by the ADHERE trial and real-world evidence. By extending the reach of this transformational therapy to thousands more patients, argenx continues to bring efgartigimod, our first-in-class FcRn blocker, to more patients in Japan and around the world suffering from severe autoimmune disease.” CIDP is a progressive, immune-mediated rare and debilitating neuromuscular disorder of the peripheral nervous system. Patients experience a range of disabling mobility and sensory issues, including trouble standing from a seated position, pain and fatigue, and frequent tripping or falling. Many patients become wheelchair bound and are unable to work as the disease progresses. Currently, 85% of patients require ongoing treatment and nearly 88% of treated patients experience residual impairment and disability. The MHLW approval is based on the ADHERE Study, the largest clinical trial to date studying CIDP. In the ADHERE study, 69% (221/322) of patients treated with VYVDURA, regardless of prior treatment, demonstrated evidence of clinical improvement, including improvements in mobility, function and strength. ADHERE met its primary endpoint (p<0.0001) demonstrating a 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in the risk of relapse versus placebo. Ninety-nine percent of trial participants elected to participate in the ADHERE+ open-label extension. The safety results were generally consistent with the known safety profile of VYVDURA in previous clinical studies and real-world use. VYVDURA was approved by the MHLW for manufacturing and marketing in January 2024 and launched in April 2024 for the treatment of generalized myasthenia gravis (gMG). In March 2024, VYVDURA was designated as an Orphan Drug for the treatment of CIDP by the MHLW. See FDA-approved Important Safety Information below and full Prescribing Information for VYVDURA, which is marketed as VYVGART Hytrulo in the United States, for additional information. What is VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc)? VYVGART HYTRULO is a prescription medicine used for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). IMPORTANT SAFETY INFORMATION Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting. VYVGART HYTRULO may cause serious side effects, including: Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART HYTRULO treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction. Before taking VYVGART HYTRULO, tell your doctor if you: What are the common side effects of VYVGART HYTRULO? The most common side effects in efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives. These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088. Please see the full Prescribing Information for VYVGART HYTRULO and talk to your doctor. About ADHERE Trial Design The ADHERE trial was a multicenter, randomized, double-blind, placebo-controlled trial evaluating VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). ADHERE enrolled 322 adult patients with CIDP who were treatment naïve (not on active treatment within the past six months or newly diagnosed) or being treated with immunoglobulin therapy or corticosteroids. The trial consisted of an open-label Stage A followed by a randomized, placebo-controlled Stage B. In order to be eligible for the trial, the diagnosis of CIDP was confirmed by an independent panel of experts. Patients entered a run-in stage, where any ongoing CIDP treatment was stopped and in order to be eligible for Stage A had to demonstrate active disease, with clinically meaningful worsening on at least one CIDP clinical assessment tool, including INCAT, I-RODS, or mean grip strength. Treatment naïve patients were able to skip the run-in period with proof of recent worsening. To advance to Stage B, patients needed to demonstrate evidence of clinical improvement (ECI) with VYVDURA. ECI was achieved through improvement of the INCAT score, or improvement on I-RODS or mean grip strength if those scales had demonstrated worsening during the run-in period. In Stage B, patients were randomized to either VYVDURA or placebo for up to 48 weeks. The primary endpoint was measured once 88 total relapses or events were achieved in Stage B and was based on the hazard ratio for the time to first adjusted INCAT deterioration (i.e. relapse). After Stage B, all patients had the option to roll-over to an open-label extension study to receive VYVDURA. About VYVDURA VYVDURA is a subcutaneous combination of efgartigimod alfa, a human IgG1 antibody fragment marketed for intravenous use as VYVGART, and recombinant human hyaluronidase PH20 (rHuPH20), Halozyme’s ENHANZE® drug delivery technology to facilitate subcutaneous injection delivery of biologics. In binding to the neonatal Fc receptor (FcRn), VYVDURA results in the reduction of circulating IgG. It is the first-and-only approved FcRn blocker administered by subcutaneous injection for the treatment of CIDP. VYVDURA is the proprietary name in Japan for subcutaneous efgartigimod alfa and recombinant human hyaluronidase PH20. It is marketed under different proprietary names in other regions. About Chronic Inflammatory Demyelinating Polyneuropathy Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare and serious autoimmune disease of the peripheral nervous system. Although confirmation of disease pathophysiology is still emerging, there is increasing evidence that IgG antibodies play a key role in the damage to the peripheral nerves. People with CIDP experience fatigue, muscle weakness and a loss of feeling in their arms and legs that can get worse over time or may come and go. These symptoms can significantly impair a person’s ability to function in their daily lives. Without treatment, one-third of people living with CIDP will need a wheelchair. About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, Israel, the EU, the UK, Canada and China. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram. SOURCE: argenx

Clinical ResultDrug ApprovalOrphan DrugImmunotherapy

100 Deals associated with Efgartigimod Alfa

External Link

KEGG	Wiki	ATC	Drug Bank
-	Efgartigimod Alfa	-	DB15270

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Purpura, Thrombocytopenic, Idiopathic	JP	argenx SE	26 Mar 2024
Myasthenia Gravis	US	arGEN-X BV	17 Dec 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	NDA/BLA	CN	Zai Lab (Shanghai) Co., Ltd.	24 Apr 2024
Primary Sjögren's syndrome	Phase 3	US	argenx SE	04 Dec 2024
Antisynthetase Syndrome	Phase 3	US	argenx SE	12 Sep 2023
Antisynthetase Syndrome	Phase 3	AR	argenx SE	12 Sep 2023
Antisynthetase Syndrome	Phase 3	AT	argenx SE	12 Sep 2023
Antisynthetase Syndrome	Phase 3	BE	argenx SE	12 Sep 2023
Antisynthetase Syndrome	Phase 3	BG	argenx SE	12 Sep 2023
Antisynthetase Syndrome	Phase 3	CY	argenx SE	12 Sep 2023
Antisynthetase Syndrome	Phase 3	CZ	argenx SE	12 Sep 2023
Antisynthetase Syndrome	Phase 3	DK	argenx SE	12 Sep 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04687072 (ADVANCE SC, CTgov)	Phase 3	Purpura, Thrombocytopenic, Idiopathic	207	Efgartigimod PH20 SC (Efgartigimod PH20 SC)	jabfpgxflx(lwdatbqsao) = qrtlypxspg cskcatfggb (mmjzwisrtf, dxatoohwoa - xxhepwaicf) View more	-	31 Oct 2024
				Placebo PH20 SC (Placebo PH20 SC)	jabfpgxflx(lwdatbqsao) = hkvchjzuqm cskcatfggb (mmjzwisrtf, gspuikhpdm - knfqinmxzj) View more
NCT04281472 (ADHERE, CTgov)	Phase 2	Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	322	Efgartigimod PH20 (Stage A: Efgartigimod PH20 SC)	xulsrzkzzn(spuusygvhi) = jnoiyfdcye uxqqaerotd (zqioczgbny, zkgznnsjwd - vrpsdnadaa) View more	-	20 Aug 2024
				Efgartigimod PH20 (Stage B: Efgartigimod PH20 SC)	jjvcytxawt(ditfiugoem) = lpqugozcwq txamjuowbp (njvxwqacwn, sxnjawwbqn - sdhfvrwuic) View more
NCT04735432 (ADAPT-SC, NEWS) Manual	Phase 3	Myasthenia Gravis 乙酰胆碱受体（AChR）抗体阳性	-	艾加莫德	viidrdntwd(hgczqjrapn) = aomiuyzfcz txxvxqnozw (uekjjebxau ) Met	Non-inferior	17 Jul 2024
				efgartigimod IV	viidrdntwd(hgczqjrapn) = dlepsgweto txxvxqnozw (uekjjebxau ) Met
EAN2024	Not Applicable	-	-	Efgartigimod IV	odinqfelmf(egdwpcbody) = hyfxefdhzu mgrkwgbwde (sfnaacuvcf, 2.2)	-	28 Jun 2024
EAN2024	Not Applicable	-	-	Efgartigimod IV	wqrlyjqsww(aonppwymtt) = kxeukgtftu tdzdttnyda (fwzrawlmif )	-	28 Jun 2024
				Efgartigimod SC	wqrlyjqsww(aonppwymtt) = flfadgwbia tdzdttnyda (fwzrawlmif )
EAN2024	Not Applicable	-	-	Efgartigimod	xtredckrxf(xwaluzshsx) = rfwdshxfxs eurgqzqjag (dryaewiwiu ) View more	-	28 Jun 2024
P4-14.016 (AAN2024)	Phase 2/3	Autoimmune Diseases IgG-mediated autoimmune disorders	-	Efgartigimod	qbenlguwyl(nlnzcrnyli) = malehbpcmw ebeajndvwo (gnsdmlsccw )	Positive	09 Apr 2024
				Placebo	qbenlguwyl(nlnzcrnyli) = syqgcjqira ebeajndvwo (gnsdmlsccw )
ADAPT/ADAPT+ (AAN2024)	Phase 3	Myasthenia Gravis acetylcholine receptor antibody-positive	-	Efgartigimod	mdtyxxkvcw(bysbqvklmd) = 0.3-point increase foeciygfzu (eemwktmhhc ) View more	Positive	09 Apr 2024
				Placebo
NCT04281472 (ADHERE, AAN2024)	Phase 2	Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	322	Efgartigimod PH20 SC 1000mg	yvlcjglahr(bhvwainhtg) = Most TEAEs were mild to moderate; 3 deaths occurred, none being related to treatment cfauwibedr (vuosamfktz )	Positive	09 Apr 2024
ADPT trial (MDA2024) Manual	Not Applicable	Myasthenia Gravis	17	Efgartigimod weekly infusion	uczflvjewf(eictfzeiad) = Most common side effects reported were mild infections, headache, and nausea. kutfnpauqb (qhkaqbjoul )	Positive	03 Mar 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis